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Permanent hemodialysis vascular access survival in children literature relating to permanent HD access is sparse due
and adolescents with end-stage renal disease. to the small number of patients with arteriovenous fistula
Background. Transplantation is the optimal therapy for pe- (AVF)/arteriovenous graft (AVG) treated with long-diatric end-stage renal disease (ESRD) patients, but in a subset
term chronic HD. AVF or AVG placement in pediatricof patients with peritoneal membrane failure, failed transplants
ESRD patients may be limited for a number of reasonsor poor social situations, chronic hemodialysis (HD) remains
the only option. Long-term survival of arteriovenous fistulas including the common use of peritoneal dialysis (PD) as
(AVFs) and arteriovenous grafts (AVGs) in pediatric patients a dialysis modality, early transplantation, and the percep-
has not been well described. tion that small patient size increases the complicationMethods. We studied the survival of permanent vascular
rate for this access. As pediatric dialysis patients surviveaccess in 34 pediatric ESRD patients treated with chronic HD
longer, develop peritoneal membrane failure or returnat our institution between 1/1/89 and 12/1/95 and followed to
12/31/2000. to dialysis after a failed renal transplant, a significant
Results. Twenty-four AVFs and 28 AVGs were created in 19 number of children may need chronic HD for extended
and 23 patients, respectively. Mean age and weight at insertion
periods of time. Creation and preservation of permanentwere 15.1 years (range 7.1 to 20.9) and 46 kg (18 to 81) for
HD access becomes a critical issue in these children withAVFs and 13.3 years (3.8 to 21.1) and 41.5 kg (10.5 to 145)
for AVGs. Fifteen patients weighed 35 kg at the time of ESRD.
access creation (7 AVFs in 5 patients, 14 AVGs in 13 patients). While cuffed venous catheters (CVCs) serve well in
Excluding primary failures, one-year, three-year and five-year small children, whose small vessel caliber is not amenable
patency rates for AVFs (74%, 59%, 59%) and AVGs (96%,
to placement of a permanent access, venous catheters69%, 40%) were not significantly different. Patency did not
are often problematic because of frequent infection,correlate with patient weight or age at access creation. Primary
access failure occurred more often (P  0.01) in AVFs (8/24) thrombosis, interrupted flow, poor position, or occur-
compared to AVGs (1/28). Access thrombosis, stenosis and rence of central venous stenosis. In addition, median
infection occurred more frequently in AVG (P  0.02). survival of CVCs has been reported to be in the range
Conclusions. Both AVF and AVG function well even in
4.0 to 10.6 months [1–4]. Data for long-term actuarialsmall pediatric patients and have survival rates equivalent to
survival and complication rates of AVFs and AVGs inadult series and longer than cuffed venous catheters in pediatric
patients. Both AVFs and AVGs are preferable for long-term pediatric and adolescent patients are lacking. The aims
HD access in pediatrics. of the present study were to analyze the five-year patency
rates for AVFs and AVGs to determine complication
rates for each access type, and to compare the suitability
Insertion and maintenance of vascular access for he- of AVFs and AVGs for long-term HD access in pediatric
modialysis (HD) is a critical aspect of taking care of end- patients receiving chronic HD.
stage renal disease (ESRD) patients on HD. Pediatric
METHODS
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The charts of all pediatric patients with ESRD treatedpediatric hemodialysis, stenosis, graft failure, end-stage renal disease,
kidney and children. with chronic HD for a minimum of one month at Texas
Children’s Hospital, Houston, Texas between January 1,Received for publication December 3, 2001
1989 and December 1, 1995 were reviewed. Age, gender,and in revised form May 17, 2002
Accepted for publication June 17, 2002 ethnicity, original disease leading to ESRD, use of ste-
roids and age at onset of ESRD were noted as well as 2002 by the International Society of Nephrology
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details regarding the type of access used, date of creation, actuarial survival of functioning access. Log-rank analy-
sis was used to determine differences between survivalduration of function, complications and interventions
during this six-year period. Data regarding patency of curves of functional AVFs and AVGs. Accesses that
were still patent at the end of the study period, at thethe AVFs/AVGs were obtained for the ten-year period
from January 1, 1989 through December 31, 1999. All time of change in modality, or in patients who were
transplanted or transferred from the unit were consid-permanent access was placed either by a pediatric sur-
geon or by an adult vascular surgeon at our hospital. ered as censored for survival analysis purposes. Linear
regression was used to determine correlation of patientThe respective surgeons performed all surgical revisions.
Pre-access placement screening included a careful his- age and weight at access insertion with access patency.
tory and physical examination. All patients with a past
history of prior catheter use or multiple access place-
RESULTS
ments underwent formal venography to delineate vascu-
Demographicslar anatomy.
In order to avoid rethromboses, either after new access Records of all 47 patients (32 male, 15 female) who
received chronic HD at our institution during the studycreation or after surgical thrombectomy, careful atten-
tion was paid to maintenance of systolic blood pressures period were reviewed. Eleven patients (23.4%) were Cau-
casian, 15 (31.9%) were African American, 19 (40.4%)and avoidance of dehydration and/or a high hematocrit
in the immediate post operative period. Routine antico- were Hispanic, and 2 (4.3%) were Asian. The median
patient age at the start of chronic HD was 13.1 yearsagulation after access thrombectomy in the post-opera-
tive period was not used. An antiplatelet agent in the (range 0.9 to 21.3). Median time for treatment with
chronic HD for these 47 patients was 16.9 months (rangeform of aspirin was used in patients with recurrent access
thromboses. 1.9 to 99.3). Twenty of 47 patients (42.6%) had both
CVC and permanent access creation at different timesVenograms and angioplasties were performed in an out-
patient setting by interventional radiologists experienced during the length of the study, 13 patients (27.7%) had
CVC access only, and 14 patients (29.7%) had permanentwith both adult and pediatric vascular access. Surveil-
lance venograms were performed at three-month inter- access only. Permanent access was created preemptively
weeks to months before starting chronic HD in thosevals in patients with recurrent thromboses and at six-
month intervals in patients with no clinical problems. patients who had permanent access only.
A total of 34 of 47 (72.3%) patients, of which 23 wereOther indications for venograms included clinical param-
eters such as an abnormal physical exam of the access, male and 11 female, had the creation of one or more
permanent access at some time during their HD course.high dialyzer venous pressure or prolonged bleeding
after needle removal at the end of dialysis as well as a Of these, eight had both AVF and AVG placed at differ-
ent times. A total of 52 permanent accesses (24 AVFsmeasured increase in access recirculation.
in 19 patients and 28 AVGs in 23 patients) were created
Definitions during the study period. Twenty-three patients required
only a single access creation, while the other 11 patientsPrimary access patency was defined as the time from
access creation to the first intervention. Secondary access had two to four permanent access creations per patient.
Fifteen patients were small, weighing between 10 andpatency was the cumulative time from access creation
to failure (not salvaged). Primary access failure was de- 35 kg at the time of permanent access creation (7 AVFs
in 5 patients, 14 AVGs in 13 patients; both an AVF andfined as non-patent access at six weeks, while interven-
tion was surgical revision, thrombectomy or balloon an- AVG in 3/15 patients). No significant difference was
noted in the demographics between patients with AVFsgioplasty performed to maintain access patency.
and AVGs (Table 1).
Statistical methods
SitesStatistically significant differences between demograph-
ics or complications of AVFs versus AVGs were deter- The most common site (22/24) for an AVF was the
wrist (Brescia-Cimino fistula). The other two AVFs weremined by Fisher’s exact test or Chi square analysis. Fac-
tors associated with primary access failure as well as placed in the upper arm and in the thigh. The most
common sites for AVG placement were in the thighsubsequent complications were analyzed using Fisher’s
exact test or Chi square tests for statistical difference (14/28) and forearm (12/28). Two AVGs were placed in
the upper arm. Five of the 14 thigh AVGs were placedbetween groups. The unpaired t test was used to deter-
mine differences in mean insert ages and weights for as a first access due to small patient size (mean age 6.0
years, mean weight 15.5 kg). Two of the 14 thigh AVGseach access type. Kaplan-Meier survival curves were gen-
erated to assess access survival. Primary access failures were placed at that site to avoid pain from needle sticks,
since the patients had spina bifida with decreased lowerwere excluded in the analysis in order to determine the
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Table 1. Demographics of patients with AVG and AVF weighing 10-35 kg (3/7, 42.8%) compared to patients
weighing 35 kg (5/17, 29.4%). When patients with pri-AVF AVG
mary AVF failure were compared to those with a func-N access (N patients) 24 (19) 28 (23)
% Male 63 73.9 tional AVF at six weeks, no significant difference was
% African American 42.1 43.5 noted for age at insertion [median age 14.1 years (range
% Hispanic 42.1 47.8
11.3 to 20.9 years) vs. 15.9 years (range 7.1 to 19.8 years),% GN (% FSGS) 54 (25) 29 (14)
% With history of steroid use 58 43 respectively] or weight at insertion [median 48 kg (range
Mean (median) age in years at access 15.1 (15.6) 13.3 (13.6) 30 to 71 kg) vs. 41.0 kg (range 18 to 81 kg), respectively].
insertion [range] [7.1–20.9] [3.8–21.1]
Primary AVF failure did not correlate with gender, eth-Mean (median) weight in kg at access 46.0 (43) 41.5 (35)
insertion [range] [18–81] [10.5–145] nicity, history of FSGS or steroid use.
N patients 35 kg at access insertion 5a 13a Other complications. Thirty-six separate complication
N (%) with previous TX 3 (15.8) 8 (34.8)
episodes occurred in 13 of 16 (81.3%) AVFs over 322N (%) with history of PD 5 (26.3) 11 (47.8)
Mean N (range) accesses per patient access-months, resulting in a complication rate of 1.3 per
prior to functioning AVF/AVG 2.7 (0–10) 3.3 (0–12)b 12 access-months. This rate was significantly lower (P 
N (%) placed 4 weeks prior to HD
0.02) compared to the AVG complication rate of 2.9 perstart 9 (37.5) 7 (25.0)
12 access-months (158 complications in 21/27 AVGs overa P  0.05
b Six AVG had failed AVF 648 access-months). Access stenosis and infection epi-
sodes were significantly lower for AVFs, but the rate of
thrombotic episodes was not significantly different for
AVFs compared to AVGs. Stenosis and thrombosis rates
limb sensation. The other seven thigh AVGs were placed were not significantly affected by gender, ethnicity or
in five patients (mean age 15.2 years, mean weight 32 history of FSGS or steroid use.
kg) after failure of one or more upper arm permanent
accesses. Venogram evaluation of these patients showed Interventions
either subclavian vein stenosis (4/5 patients) or inade- Thirty-seven interventions for thromboses or venous
quate upper extremity vasculature (1/5 patients). stenosis were performed in 10 of 16 (62.5%) AVFs over
322 months (1.38 interventions per 12 access-months),Survival
which was significantly less than 149 interventions in
During the 10-year study period, primary access failure 16 of 27 (59.2%) AVGs over 648 access-months (2.76
occurred in eight AVFs (33.3%) and one AVG (3.7%; interventions per 12 access-months; Table 3). The total
Table 2). One year actuarial primary patency rate exclud- number of interventions was significantly higher in AVGs
ing primary access failure was 50% for AVF and 41% (P  0.05); however, the percentage of accesses in each
for AVG (P  NS). After excluding primary access fail- group requiring intervention was not significantly differ-
ures, the one-year actuarial secondary patency rates were ent (P  0.16).
74% for AVFs and 96% for AVGs, much higher than the
30 to 60% secondary patency rates reported for CVCs in
DISCUSSIONpediatric patients [1–4]. Actuarial cumulative survival
over five years was not significantly different for AVFs The literature contains very little data regarding the
or AVGs (Fig. 1). Overall, secondary patency rates at success of permanent vascular access in pediatric patients
one, three and five years for AVFs were 74%, 59% and [1, 5, 6]. Few studies report rates of primary vascular
59%, respectively. One, three and five year secondary access failure [5, 6] or patency [1, 5, 6], and no studies
patency rates for AVGs were 96%, 69% and 40%, re- report long-term actuarial survival analysis for pediatric
spectively. No correlation was noted between the insert vascular access. To our knowledge, this study is the first
age or weight and secondary patency of the vascular to confirm that primary failure of AVFs and AVGs and
access. Cumulative AVF and AVG survival did not differ long-term patency rates are comparable to results for
significantly after stratification for patient weight at in- adults [7–15]. Primary failure rates for AVFs in adults
sertion ( or 35 kg) or access site. are reported in the 8 to 40% range [7, 13, 14], which is
similar to the 33.3% failure rate found in our study.
Complications Primary AVF failure did not correlate with smaller pa-
tient size or younger age in our pediatric patients, sug-Primary failure. Primary access failure occurred sig-
nificantly more often with AVFs (8/24, 33.3%) than with gesting that early AVF function is probably more depen-
dent on surgical expertise and vessel integrity than vesselAVGs (1/28, 3.6%; P 0.01; Table 2). Creation of AVFs
in patients of smaller size and younger age did not ex- caliber.
Reported one-year primary patency rates for AVFsplain the rate of primary AVF failure. Rates for primary
AVF failure were not significantly different for patients and AVGs in adults are in the range of 40 to 60% [7–10],
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Table 2. Complications in AVFs and AVGs in pediatric ESRD patients on maintenance HD (1989–1999)
Complication AVF AVG P value
Primary failure % 8 (33.3%) 1 (3.6%) 0.009
% without complications 23.5%a 22.2%a NS
N access-monthsa 322 648
Total N of complications (total N accesses) 36 (13) 158 (21) 0.03b
Incidence of complications per 12 access-months 1.3 2.9
N stenosis episodes (N accesses) 9 (3) 57 (14)
Incidence of stenosis per 12 access-months 0.33 1.06
N thrombosis episodes (N accesses) 21 (8) 71 (15) NSb
Incidence of thrombosis per 12 access-months 0.78 1.31
N pseudoaneurysms (N accesses) 3 (2) 5 (3) NSb
Incidence of pseudoaneurysms per 12 access-months 0.11 0.09
N infections (N accesses) 3 (3)c 26 (14)c 0.03b
Incidence of infections per 12 access-months 0.11 0.48
a Excluding accesses with primary failure
b Comparison made between the number of affected accesses in both groups
c Four were AVG infections with bacteremia, one required excision; the remaining were superficial infections of the overlying skin; no deep AVF infections or
AVF infections associated with bacteremia occurred
Fig. 1. Actuarial survival of arteriovenous
fistula (AVF; dark gray line) and arteriove-
nous graft (AVG; black line) in pediatric end-
stage renal disease (ESRD) patients on chronic
hemodialysis from 1989 to 1999. Symbols are:
() irreversible failure; () censored. P 0.81.
similar to the primary patency rates for pediatric patients strates that the K-DOQI guidelines recommended for
adults also can be achieved in pediatric patients. In addi-in our study. The one-year secondary patency rates for
adults are reported to be in the range of 52 to 80% for tion, our study did not demonstrate a decrease in one-,
three- or five-year permanent vascular access patencyAVFs and 54 to 83% for AVGs, respectively [7–15].
Recent K-DOQI guidelines for vascular access in adults rates for patients of smaller size or younger age, sug-
gesting that permanent vascular access can be successfulsuggest aiming for one- and three-year patency rates of
70% and 50% for AVGs, respectively [16]. Patency rates in most pediatric patients, even those as small as 10 to
35 kg.at one and three years in our study were 74% and 59%
for AVFs and 96% and 69% for AVGs, respectively, As expected, complications occurred more frequently
with AVGs compared to AVFs in our study. Episodeswhich are similar to the rates reported for adults and
the suggested K-DOQI guidelines for AVGs. Few data of stenosis and infection were more common for AVGs
than AVFs, but the frequency of episodes of thrombosisare available to allow formulation of evidence-based pe-
diatric vascular access guidelines. Our study demon- were similar. During most of the 10 years of this study,
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Table 3. Interventions required in AVF and AVG in pediatric pediatric age group, with usage as high as 77% compared
ESRD patients (1989–1995)
to 11% AVFs and 12% AVGs reported for 682 children
AVF AVG in North America (NAPRTCS database) [1]. One-year
Interventions (N  16)a (N  27)a survival time for CVCs in children ranges from 27 to
N balloon angioplasty (N access) 5 (3) 48 (12) 62% [1, 2, 4], which is similar to the survival time of
N surgical revision (N access) 11 (5) 30 (10)
CVCs at our center [3] and much lower than the one-N surgical thrombectomy (N access) 21 (8) 71 (15)
Total N interventions 37 (10) 149 (16) year actuarial survival rates of 74% for AVFs and 96%
Intervention rate per 12 access-months 1.38 2.76 for AVGs demonstrated in our study. AVF and AVG
aExcluding primary failures survival rates at three and five years decrease (59% and
59% for AVF; 69% and 40% for AVG, respectively),
but are comparable to AVG rates at those times for
adults. Actuarial survival over five years is not different
we had an active AVG venogram surveillance program
for patients weighing 10 to 35 kg compared to 35 kg.
designed to detect and monitor progression of stenosis
The data of this study strongly suggest that if long-term
with early appropriate intervention to prevent actual HD is anticipated in pediatric ESRD patients 10 kg,
thrombosis. Interventions were more frequent for AVGs permanent vascular access should be the vascular access
compared to AVFs (2.76 vs. 1.38 interventions per 12 of choice. Early creation of an AVF with ample matura-
access-months), which may have led to reduced throm- tion time is desirable for the best outcome. Vigilant sur-
bosis rates and increased patency rates for AVGs, and veillance and early intervention for access complications
account for the similarity of actual thrombotic episodes may continue to improve AVF and AVG survival. Judi-
between the AVF and AVG groups. Our AVG interven- cious use of permanent HD access in pediatrics will pre-
tion rate is similar to the three interventions per graft- serve vascular sites for use later in life and improve the
year for adults reported recently by Dixon, Novak and long-term outcome in pediatric and adolescent ESRD
Fangman [7]. patients.
Focal segmental glomerulosclerosis is a common dis-
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